In order to plan the way it should be administered to vulnerable countries, the World Health Organization has approved the Pfizer/BioNTech emergency vaccine.
This is the first vaccine to be added to the list of urgent use of UN organisations (EUL).
WHO and its own teams, WHO regulatory experts from all over the world reviewed data on the Pfizer/BioNTech vaccine and on Thursday found that the WHO fulfilled the safety and efficacy specifications with their advantages that offset possible risks.
Dr Mariangela Simao, WHO Assistant Director General for Access to Medicines and Health Goods, said in a statement “this is a very positive step towards achieving global access to Covid-19 vaccines.
“I want to underline the need for an even greater international effort to achieve sufficient supply of vaccines to meet priorities across the country.” ” ”
The move allows countries access to accelerate the process of importing and delivering the vaccine through regulatory approvals.
The vaccine can also be obtained for distribution to countries in need through Unicef and the Pan American Health Organization (PAHO).
At the same time, WHO has expressed encouragement to more developers to study and analyse the vital supply for all countries to avoid the pandemic globally.
“Night andday, WHO and our partners are working to evaluate the safety and efficacy of other vaccines,” said Dr. Simao.
“The vaccine is being tested as well. The committee will convene on 5 January to devise new policies and guidelines for the vaccines based on the recommendations on the population priorityisation of Covid-19 vaccines issued by the WHO Strategic Consultation Group of Immunization Experts (SAGE).
The WHO works with regional partners in promoting the two-dose shot and its expected benefits to the national health authorities
A global initiative called COVAX to ensure an equal distribution of vaccines to all countries and not just the rich nations is driven by the World Health Organisation, the GAVI Vaccines Alliance and the Coalition for epidemical preparedness developments.
Meanwhile, German company BioNTech said Friday that it raced to increase its Covid-19 production in Europe to fill the “gap” created by the lack of additional approved vaccines.
BioNTech and its US partner Pfizer produced this vaccine in late December for the first time in the European Union. Countries like Great Britain, Canada and the USA have earlier approved the vaccine for Pfize/BioNTech, and since then, US company Moderna and Oxford/AstraZeneca have also provided green-light jabs, leaving behind the inoculation drive of the EU.